Clinical Trials > All Submitted Clinical Trials

It is not the intention of the Cholangiocarcinoma Foundation to provide specific medical advice.  We provide website users with information to help them better understand their health conditions and the current approaches related to prevention, diagnosis, treatment and supportive care. You are urged to always seek the advice of your physician or other qualified healthcare provider.

Now Enrolling

NCI/CTEP 10276: A Phase 1/2 Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

The phase II portion of this trial studies how well peposertib (a drug that may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth) works with avelumab and hypofractionated radiation therapy in treating patients with hepatobiliary malignancies that have spread to other places in the body (advanced/metastatic).

Read More

FIRST-308

This is a randomized study to compare the effectiveness of tinengotinib against standard of care chemotherapy in patients who have received prior chemotherapy and one prior FGFR inhibitor (third line of treatment). Tinengotinib is an FGFR inhibitor, which is taken orally once a day. The control arm will be chemotherapy chosen by your physician.

Read More

Effects of Exercise and Nutritional Interventions During Platinum Chemotherapy on Neuropathy: Examining the Interoceptive Brain System and Inflammation

Chemotherapy-induced peripheral neuropathy (CIPN) is a highly prevalent and severe side-effect of platinum-based chemotherapy, often used to treat gastrointestinal cancers. There are very limited treatments for CIPN. This is a phase II randomized controlled trial to test the preliminary efficacy of exercise vs. nutrition education on CIPN.

Read More

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer

This phase II trial compares the effect of adding bevacizumab and atezolizumab to gemcitabine and cisplatin (chemotherapy) versus chemotherapy and atezolizumab in treating patients with combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA) that cannot be removed by surgery (unresectable) or that may have spread from where it first started.

Read More

Safety and Tolerability of TNG462 in Patients with MTAP-deleted Solid Tumors

This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally.

Read More

A Phase 2a, double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 when added to standard of care (SoC) versus standard of care alone in subjects with advanced solid tumors (BOLSTER)

This trial evaluates a new drug, LSTA1, or placebo when added to gemcitabine, cisplatin, and durvalumab as a potential new treatment for metastatic or unresectable cholangiocarcinoma or gallbladder carcinoma patients.

Read More

A Phase 2 study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

This is a study for patients with advanced, unresectable intra or extrahepatic cholangiocarcinoma (iCCA or eCCA) with fibroblast growth factor receptor FGFR2 fusions or rearrangements. This is an open label study.

Read More

Safety and Tolerability of TNG908 in Patients with MTAP-deleted Solid Tumors

Study Name Safety and Tolerability of TNG908 in Patients with MTAP-deleted Solid Tumors ClinicalTrials.gov Identifier (if applicable) NCT05275478 Clinical Trial Category (check all that apply) Beyond First Line Therapy Targeted Therapy Study Center Institution Name NEXT Oncology Institution Address 2829 Babcock Road City San Antonio State Texas Zip Code 78229 Country United States List additional…

Read More

Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases

This phase I trial studies the side effects and effect of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) nab-paclitaxel in combination with gemcitabine and cisplatin in treating patients with biliary tract cancer that has spread to the peritoneum (peritoneal metastases).

Read More

TS-PERIO-02 – ACTIVE, NOT RECRUITING

Study Name TS–PERIO–02 ClinicalTrials.gov Identifier (if applicable) NCT05220722 Clinical Trial Category (check all that apply) Beyond First Line Therapy Immunotherapy Other Novel Therapy Study Center Institution Name MD Anderson Cancer Center City Houston State Texas Country United States List additional Institutions (include address, phone number, and website) Rhode Island Hosptial at Brown University of Colorado…

Read More